
|Articles|August 27, 2008
FDA speeds up review of Droxidopa
The drug is marketed in Japan to treat low blood pressure.
Advertisement
The Food and Drug Administration has given fast-track designation to Droxidopa, which is marketed in Japan to treat low blood pressure. Such a designation is reserved for drugs that treat serious conditions for which there is an unmet need. The maker of the drug, Chelsea Therapeutics International, says it plans to seek marketing approval for Droxidopa after completing clinical trials this year.
To see more Daily News articles,
To go to the Drug Topics homepage,
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Prodigious PBM Pivot: How Supply Chain Entities Will Move Forward After CAA 2026
2
Executive Order Calls for Realignment of Childhood Vaccines
3
Q&A: Pharmacists Can Address ADA Standards Across All Settings
4
Embedded Pharmacists Are Vital Yet Underutilized in Diabetes Care
5





























































